PFIZER INC business relationships

“(4) Adcetris is commercialized in collaboration with Takeda.” SEC filing

“(c) VLA15 is being developed in collaboration with Valneva SE.” SEC filing

“In May 2023, we and BioNTech amended our contract with the EC to deliver COVID-19 vaccines to the EU.” SEC filing

“(15) Ngenla is licensed from OPKO Health, Inc., and is developed and commercialized by Pfizer, including in the U.S., Latin America, Europe, Africa, and Asia.” SEC filing

“(18) Product is being commercialized in collaboration with BioNTech.” SEC filing

“(c) Tivdak is commercialized in collaboration with Genmab A/S.” SEC filing

“(d) Disitamab vedotin is being developed in collaboration with RemeGen Co., Ltd.” SEC filing

“...omotion rights in the U.S. Outside the U.S., Genmab has the sole right to promote Tivdak for second-line plus mCC and has co-promotion rights for other indications in all territories except certain territories where Zai Lab has commercialization rights (mainland China, Hong Kong, Macau, and Taiwan).” SEC filing

“(b) Emblaveo is being developed in collaboration with AbbVie.” SEC filing

“In certain smaller countries, Pfizer has full commercialization rights and BMS supplies the product to Pfizer at cost plus a percentage of the net sales price to end-customers, which is recorded in full upon transfer of control of the product to Pfizer.” SEC filing

“BMS, along with its partner Pfizer, settled with a number of these generic companies and won at the trial and appellate levels against others.” SEC filing

“The application is based on data from the Phase 3 KEYNOTE-905 trial conducted in collaboration with Pfizer and Astellas.” SEC filing

“*1 Partnership with Pfizer Inc.” SEC filing

“Collaborations: (a) ImmuNext; (b) Regeneron; (c) Recludix; (d) Pfizer” SEC filing

“Therefore, for the year ended December 31, 2022, the accumulated revenue recognized since the inception of the agreement with Pfizer amounting to €45.9 million was reversed as other revenues from contracts with customers.” SEC filing

“In regards to our Borrelia vaccine candidate VLA15 which is currently licensed to Pfizer, as of December 31, 2025, we own a patent family which includes 8 issued U.S. patents, 1 pending U.S. patent application, and 2 European patents that are validated, one in 38 of the European Patent Convention me...” SEC filing

“Other Revenues and Refund Liabilities - Research Collaboration and License Agreement with Pfizer” SEC filing

“We are awaiting results from the pivotal, placebo-controlled efficacy clinical trial, "Vaccine Against Lyme for Outdoor Recreationists (VALOR)" in the first half of 2026, conducted by our partner Pfizer.” SEC filing

“• In January 2026, we entered into a license agreement with Pfizer for use of our Matrix-M TM adjuvant in vaccine development.” SEC filing

“Pursuant to the Pfizer-Priovant License Agreement, Pfizer granted Priovant (i) an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and (ii) a non-exclusive, worldwide, sublicensable, royalty-bearing license under certain know-how, in each case, to develop, manufactu...” SEC filing

“License and Collaboration Agreement with Pfizer, Inc.” SEC filing

“| | | Manufacturing and Supply Agreement, dated as of November 16, 2020, by and between Viatris Inc. (as Manufacturer) and Pfizer Inc. (as Customer), filed as Exhibit 10.6 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference. ^ |” SEC filing

“| | | Manufacturing and Supply Agreement, dated as of November 16, 2020, by and between Pfizer Inc. (as Manufacturer) and Viatris Inc. (as Customer), filed as Exhibit 10.5 to the Report on Form 8-K filed by Viatris Inc. with the SEC on November 19, 2020, and incorporated herein by reference.^ |” SEC filing

“| | | Patent and Know-How License Agreement (Pfizer as licensor), dated February 6, 2013, by and between Zoetis Inc. and |” SEC filing

“We are dependent on Pfizer to prosecute, maintain and enforce certain intellectual property.” SEC filing

“The Company accounts for the Pfizer Agreement under ASC 606, as it includes a customer-vendor relationship as defined under ASC 606 and meets the criteria to be considered a contract.” SEC filing

“During the collaboration term, Pfizer had a one-time option to substitute a disease that is the subject of a specific program with one pre-defined substitute disease.” SEC filing

“collaboration partner Pfizer, higher expenses from inventory scrapping and write-downs to net realizable value” SEC filing

“Because the information supplied by Pfizer is” SEC filing

“Retacrit ® is licensed from Pfizer Inc. since 2015 for certain channels, primarily comprising the U.S. non-hospital dialysis market and nephrology office practices.” SEC filing

“Our partners Pfizer and AbbVie are” SEC filing

“the off-market buyback contract with Pfizer,” SEC filing

“consumer healthcare joint venture (the Pfizer” SEC filing

“purchase from Pfizer during 2025 under the” SEC filing

“In addition to the CTP patents and applications licensed to Pfizer, OPKO has multiple patent families covering similar biologicals with patents and applications pending in the U.S. and internationally.” SEC filing

“Amended and Restated Development and Commercialization License Agreement by and between Pfizer Inc. and OPKO Ireland Ltd., dated May 12, 2020, filed with the Company's Quarterly Report on Form 10⁃Q filed with the Securities and Exchange Commission on July 31, 2020 for the Company's three-month perio...” SEC filing

“We have partnered with Pfizer Inc. ("Pfizer") for further development and commercialization of Somatrogon (hGH-CTP).” SEC filing

“We are substantially dependent on Pfizer for the successful commercialization of such product.” SEC filing

“Pfizer (in collaboration with OPKO Health Inc.) has received regulatory approval of once-weekly somatrogon (brand name NGENLA) in more than 40 countries for pediatric GHD.” SEC filing

“Revenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.” SEC filing

“Following the execution of the Pfizer Agreement, we are the owner of, co-owner of, or the licensee of multiple patents and patent applications in the United States and worldwide.” SEC filing

“...rograms, our patent rights are generally composed of patents and pending patent applications that are solely owned by us, co-owned with Servier, co-owned with Cellectis, co-owned with Pfizer, exclusively licensed from Pfizer, exclusively licensed from Servier, or exclusively licensed from Cellectis.” SEC filing

“Collaboration Agreement by and between Servier and Pfizer, dated October 30, 2016, which Pfizer assigned to the Company in April 2018, will survive the termination of the Original Cellectis Agreement.” SEC filing

“In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement").” SEC filing

“In July 2021, we announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant.” SEC filing

“License agreement with Pfizer” SEC filing

“Sciences, Inc. and Pfizer, Inc./EMD Serono, Inc. Most of these companies, either alone or together with their collaborative partners,” SEC filing

“depend on intellectual property licensed from Pfizer for our” SEC filing

“Settlement and License Agreements with Pfizer” SEC filing

“Pursuant to the Collaboration and License Agreement, Pfizer made an upfront, non-refundable $80.0 million payment to us.” SEC filing

“...e 2014, we entered into a Research Collaboration and License Agreement (the "Collaboration and License Agreement") with Pfizer, Inc. ("Pfizer") pursuant to which we agreed to collaborate to conduct discovery and pre-clinical development activities to generate CAR T-cells directed at Pfizer- and Cell...” SEC filing

“WinHealth has established partnerships with international companies that include Boehringer-Ingelheim, Janssen, Novartis, Pfizer and Roche, generating several hundred million dollars in sales annually.” SEC filing

“Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johnson & Johnson, Merck, Novartis, Pfizer and Regeneron.” SEC filing

“(1) Pursuant to Pfizer License Agreements” SEC filing

“We are collaborating with Pfizer and Gilead on the clinical development of darovasertib in UM and IDE397 for MTAP-deleted UC and NSCLC, respectively.” SEC filing

“Clinical Trial Collaboration and Supply Agreements with Pfizer for Darovasertib” SEC filing

“In November 2022, Immutep signed a new Clinical Trial Collaboration and Supply Agreement with Merck KGaA and Pfizer to conduct the INSIGHT-005 trial.” SEC filing

“Upon commercialization of any product utilizing the licensed product, the Company is required to pay to Pfizer a low single-digit royalty on net sales of product sold by the Company, its affiliates or sublicensees.” SEC filing

“For example, certain trade secrets related to maralixibat are licensed from Pfizer, and patents, patent applications and trade secrets related to volixibat are licensed from Sanofi.” SEC filing

“...for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Eli Lilly, Merck, Novartis Pharmaceuticals Corporation ("Novartis"), Pfizer, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“The Pfizer Agreement originally stipulated that should we commercialize any of the compounds licensed from Pfizer or any products containing any of these compounds, we will be obligated to pay to Pfizer incremental annual royalties between approximately 10% and 20% of net sales of all such products,...” SEC filing

“The license is exclusive with respect to certain patent rights owned by or licensed to Pfizer.” SEC filing

“Should we commercialize additional compounds licensed from Pfizer or any products containing any of these compounds, we will be obligated to pay Pfizer annual royalties at a fixed rate in the low-to-mid teens of net sales of all such products, subject to certain reductions and offsets in some circum...” SEC filing

“While the drug candidates were developed by Pfizer, both the drug substance and drug product are manufactured by third -party contractors.” SEC filing

“Avillion I is eligible to receive fixed payments from Pfizer based on this approval under its co-development agreement with Pfizer.” SEC filing

“In addition to the issued patents exclusively licensed from Pfizer, we own or co-own three patent families with claims directed to defactinib.” SEC filing

“| | ● | | our strategic collaborations and licensing agreements with, and funding from, our collaboration partners Neurocrine Biosciences, Inc. and Novartis Pharma AG and our licensee Alexion, AstraZeneca Rare Disease (successor-in-interest to former licensee Pfizer Inc.); |” SEC filing

“Option and License Agreement, by and between the Registrant and Pfizer Inc., dated October 1, 2021” SEC filing

“Under this arrangement, Pfizer is the Company's customer and revenue is recognized upon delivery of XACDURO to Pfizer at the contractually agreed prices.” SEC filing

“We will purchase the licensed products exclusively from Pfizer.” SEC filing

“In November 2024, we entered into a strategic collaboration with Pfizer that allows us to leverage the industry-leading commercialization infrastructure of Pfizer's affiliated companies in the anti-infective therapeutic area to support sales of XACDURO in mainland China.” SEC filing

“These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Novartis, Pfizer Inc., Bristol-Myers Squibb, Kyorin Pharmaceutical Corporation, and Teva Pharmaceuticals, which have significant internal research and development efforts directed at develop...” SEC filing

“Pursuant to the agreement, 90 % of the fee ($ 23.3 million) was creditable toward (i) qualifying CDX-616 orders shipped through December 31, 2023, and (ii) fees associated with new development or licensing agreements with Pfizer entered into before April 4, 2023.” SEC filing

“We supplied the CDX‑616 enzymes under an Enzyme Supply Agreement with Pfizer Ireland Pharmaceuticals, a subsidiary of Pfizer (the "Pfizer Supply Agreement").” SEC filing

“received FDA approval for Mekinist (trametinib), that was subsequently sold to Novartis AG; Pfizer Inc., which received FDA approval for” SEC filing

“In particular, several pharmaceutical companies have announced partnerships around programs targeting STAT6, and/or have their own internal STAT6 programs, including Gilead Sciences, Inc, Johnson & Johnson, Pfizer and Sanofi.” SEC filing

“In our partnership with Pfizer, which was announced in September 2023 under an agreement with Seagen, Inc., we have achieved three preclinical milestones to date, qualifying for $15.0 million in milestone payments.” SEC filing

“a collaboration and license agreement with Innovent and clinical collaboration agreements with AstraZeneca, Merck, and Pfizer, and research” SEC filing

“...are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company ("BMS"), Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme ("Sanofi") and Roche.” SEC filing

“Through our participation in the former CTx CRC, we retain a passive economic interest in a KAT6 program licensed to Pfizer.” SEC filing

“...ipants Agreement and associated CRC Commercialization License Agreements (including the existing license agreement with Pfizer relating to KAT6), for a period of 15 years from Completion; (iii) pursuant to any monetization of certain of the Company's intellectual property rights within the applicabl...” SEC filing

“Clinical Trial Collaboration and Supply Agreement with Pfizer” SEC filing

“We have established clinical collaborations with both Novartis and Pfizer and we intend to continue evaluating opportunities to work with partners that meaningfully enhance our capabilities with respect to the development and commercialization of our product candidates.” SEC filing

“Clinical Trial Collaboration and Supply Agreement with Pfizer” SEC filing

“...nies developing inhibitors against PRC2 via EZH2 inhibition that are currently in clinical trials, including Ipsen, Novartis, Daiichi Sankyo, Pfizer, Shanghai HaiHe Pharmaceutical, Treeline Biosciences in collaboration with Jiangsu HengRui Medicine Co., Evopoint Biosciences and Hanmi Pharmaceutical.” SEC filing

“Pursuant to the Amended Pfizer Agreement, the Company sold to Pfizer its share in the collaboration worldwide except for Brazil.” SEC filing

“We have licensed to Pfizer the global rights to market and sell Elelyso in all markets, excluding Brazil, pursuant to the Amended Pfizer Agreement.” SEC filing

“We have granted the marketing rights to Elelyso globally, excluding Brazil, to Pfizer through an exclusive licensing agreement.” SEC filing

“● risks relating to our ability to manage our relationship with our collaborators, distributors, and partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;” SEC filing

“Assistance in arranging for the manufacture of the drug substance by Pfizer or by alternative supplier chosen by Pfizer in consideration of an agreed hourly rate plus reimbursement of expenses.” SEC filing

“The Company determined that the supply agreement is a customer option and not a material right, as the pricing to Pfizer is not at a significant discount.” SEC filing

“The Pfizer Territory excludes the United States and the Asian markets previously licensed to Everest in the Everest Territory.” SEC filing

“Changes in deferred revenue are related to the GSK License Agreement and our license agreement with Pfizer.” SEC filing

“During the year ended December 31, 2024 we recognized $0.4 million in collaboration revenue related to our agreement with Pfizer.” SEC filing

“On August 12, 2025, we announced a major new customer in the eye health sector, comparable in scale to Pfizer and Merck, who implemented SteraMist iHP at two facilities in under four months and placed open BIT Solution orders for 2026.” SEC filing

“...rosecuting (including in connection with any reexaminations, oppositions and the like) and maintaining the licensed patent rights and to provide Pfizer a reasonable opportunity to review and comment on proposed submissions to any patent office and reasonably consider any comments provided by Pfizer.” SEC filing

“Our license agreement with Pfizer imposes upon us various diligence, payment and other obligations, including as described in the section entitled " Business - License Agreements - Pfizer Agreement ."” SEC filing

“...rosecuting (including in connection with any reexaminations, oppositions and the like) and maintaining the licensed patent rights and to provide Pfizer a reasonable opportunity to review and comment on proposed submissions to any patent office and reasonably consider any comments provided by Pfizer.” SEC filing

“...mmercialized and/or are developing such treatments for cancer including large pharmaceutical and biotechnology companies, such as AstraZeneca plc, Bristol-Myers Squibb Company, Merck, Pfizer in partnership with Merck KGaA, Regeneron Pharmaceuticals, Inc. in partnership with Sanofi Genzyme and Roche.” SEC filing

“Similarly, our clinical supply partners, such as Pfizer in the case of elranatamab, may rely on a variety of third parties in connection with the manufacturing of their products.” SEC filing

“On September 30, 2025, we entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer Inc., or the Pfizer Agreement.” SEC filing

“Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Moderna, Pfizer, Regeneron and others to develop certain PROBODY therapeutics.” SEC filing

“Under the terms of the amended and restated license agreement with Pfizer, Pfizer may currently terminate the license at any time.” SEC filing

“clients such as Disney, Cisco Systems, Pfizer, Motorola, and Microsoft, among many others.” SEC filing

“For example, we have collaborated with Pfizer, GSK and Dana Farber on the development of azenosertib.” SEC filing

“...tumor indications, including, but not limited to, ivonescimab (Summit Therapeutics Inc.), pumitamig (co-developed by BioNTech SE and Bristol Myers Squibb), LM-299 (LaNova Medicines Ltd.; in-licensed by Merck), SSGJ-707 (3SBio Inc.; in-licensed by Pfizer), and CTX-10726 (Compass Therapeutics, Inc.).” SEC filing

“Under the Information Rights Agreement, we granted Pfizer a 30-calendar day right of first negotiation ("ROFN") if we commence or engage with any third party with respect to a potential grant of rights to develop and/or commercialize a BCMA Product Candidate, including, without limitation, a license...” SEC filing

“• the expected benefits of potential strategic collaborations with third parties, including our agreements with Pfizer, and our ability to attract new collaborators;” SEC filing

“Additionally, we agreed to provide Pfizer access to any preclinical or interim or final clinical data (including raw data) and results generated as part of the development program for a BCMA Product Candidate at the same time that we provide such data to a third party (other than to our service prov...” SEC filing

“The trial enrolled 110 patients in the intent-to-treat ("ITT") population and is conducted in partnership with Pfizer Ignite, an end-to-end service for biotech companies.” SEC filing

“company that partnered with Pfizer, MedImmune, and Isu Abxis.” SEC filing

“Lasofoxifene was discovered through a research collaboration between Pfizer Inc. ("Pfizer") and Ligand Pharmaceuticals ("Ligand").” SEC filing

“branded drugs like Viagra (Pfizer) and Cialis (marketed by Lilly ICOS LLC, a joint venture between Eli Lilly and Company and ICOS Corporation)” SEC filing

“The initial licensed targets include CD123 and EDB+FN and the Company has the option to expand the scope of its license to add additional licensed targets that have not been licensed to a third party or are not the subject of a Pfizer ADC development program.” SEC filing

“Our MICVO product candidate was built utilizing the FACT Platform, initially licensed from Pfizer in December 2020, before securing an exclusive license to the FACT Platform in October 2022.” SEC filing

“...y approvals for their anti-PD-1/PD-L1 antibodies, including AstraZeneca, BeiGene/Novartis, Bristol-Myers Squibb, Merck, Pfizer in partnership with Merck KGaA, Regeneron in partnership with Sanofi Genzyme and Roche/Genentech, and there are also many other anti-PD-1 and anti-PD-L1 antibodies in clinic...” SEC filing

“Under the terms of the agreement, Pfizer is authorized to develop, manufacture, market, and commercialize products incorporating the licensed technology with respect to a specific POZ polymer structure in one field.” SEC filing

“In October 2023, Serina entered into a non-exclusive license agreement with Pfizer to use our POZ polymer technology for use in lipid nanoparticle drug delivery formulations.” SEC filing

“In December 2025, we entered into an exclusive global license agreement with Pfizer (the "Pfizer License Agreement") to develop, manufacture and commercialize ervogastat, a Phase 2 oral DGAT-2 inhibitor, and two additional early-stage MASH assets.” SEC filing

“...ducting Phase III clinical studies globally, PF-08634404 (PF'4404 / SSGJ-707), which was licensed globally, ex-China by Pfizer Inc. in July 2025, LM-299, which was licensed globally by Merck & Co., Inc. in November 2024, and RC148, which was licensed outside of Greater China by AbbVie Inc. in Januar...” SEC filing